Stock Research for cnbx

cnbx

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

cnbx Stock Chart & Research Data

The cnbx chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the cnbx chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


cnbx Due diligence Resources & Stock Charts

The cnbx stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View cnbx Detailed Price Forecast - CNN Money CNN View cnbx Detailed Summary - Google Finance
Yahoo View cnbx Detailed Summary - Yahoo! Finance Zacks View cnbx Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View cnbx Trends & Analysis - Trade-Ideas Barrons View cnbx Major Holders - Barrons
NASDAQ View cnbx Call Transcripts - NASDAQ Seeking View cnbx Breaking News & Analysis - Seeking Alpha
Spotlight View cnbx Annual Report - CompanySpotlight.com OTC Report View cnbx OTC Short Report - OTCShortReport.com
TradeKing View cnbx Fundamentals - TradeKing Charts View cnbx SEC Filings - Bar Chart
WSJ View Historical Prices for cnbx - The WSJ Morningstar View Performance/Total Return for cnbx - Morningstar
MarketWatch View the Analyst Estimates for cnbx - MarketWatch CNBC View the Earnings History for cnbx - CNBC
StockMarketWatch View the cnbx Earnings - StockMarketWatch MacroAxis View cnbx Buy or Sell Recommendations - MacroAxis
Bullish View the cnbx Bullish Patterns - American Bulls Short Pains View cnbx Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View cnbx Stock Mentions - StockTwits PennyStocks View cnbx Stock Mentions - PennyStockTweets
Twitter View cnbx Stock Mentions - Twitter Invest Hub View cnbx Investment Forum News - Investor Hub
Yahoo View cnbx Stock Mentions - Yahoo! Message Board Seeking Alpha View cnbx Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for cnbx - SECform4.com Insider Cow View Insider Transactions for cnbx - Insider Cow
CNBC View cnbx Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for cnbx - OTC Markets
Yahoo View Insider Transactions for cnbx - Yahoo! Finance NASDAQ View Institutional Holdings for cnbx - NASDAQ


Stock Charts

FinViz View cnbx Stock Insight & Charts - FinViz.com StockCharts View cnbx Investment Charts - StockCharts.com
BarChart View cnbx Stock Overview & Charts - BarChart Trading View View cnbx User Generated Charts - Trading View




Latest Financial News for cnbx


Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
Posted on Wednesday February 17, 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021, that said study results showing "a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice," are said to have statistical significance with p ≤ 0.016.


Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
Posted on Tuesday February 16, 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p £ 0.016).


Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
Posted on Wednesday February 03, 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Interim results of a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p-value=0.022. Study is ongoing.


Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
Posted on Monday December 21, 2020

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of concept (POC), in-vivo, animal model studies to test its drug candidate RCC-33 on mice transplanted with colorectal cancer tumor cell lines. Study results are to be included in the data package being prepared for submission to the US Food and Drug Administration along with a request for a pre-IND Meeting.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.